Evidence map›Paper›PMID 36382656›Full record

ArticleMolecular medicine reports2023

Inhibition of colorectal cancer tumorigenesis by ursolic acid and doxorubicin is mediated by targeting the Akt signaling pathway and activating the Hippo signaling pathway.

Dan Hu, Ruo Yu Meng, Thi Van Nguyen, Ok Hee Chai, Byung Hyun Park, Ju-Seog Lee, Soo Mi Kim

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Enhancing doxorubicin's anticancer impact in colorectal cancer by targeting the Akt/Gsk3β/mTOR-SREBP1 signaling axis with an HDAC inhibitor.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2025
    Article
  13. Article
  14. Review
  15. Potentials of N-Acyl Hydrazones Against Colorectal Cancer: A Mini Review.Anti-cancer agents in medicinal chemistry · 2025
    Review
  16. Review
  17. Natural Products Treat Colorectal Cancer by Regulating miRNA.Pharmaceuticals (Basel, Switzerland) · 2023
    Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Dan HuDepartment of Physiology, Jeonbuk National University Medical School, Jeonju, Jeollabuk‑do 54907, Republic of Korea.
Ruo Yu MengDepartment of Physiology, Jeonbuk National University Medical School, Jeonju, Jeollabuk‑do 54907, Republic of Korea.
Thi Van NguyenDepartment of Anatomy, Jeonbuk National University Medical School, Jeonju, Jeollabuk‑do 54907, Republic of Korea.
Ok Hee ChaiDepartment of Anatomy, Jeonbuk National University Medical School, Jeonju, Jeollabuk‑do 54907, Republic of Korea.
Byung Hyun ParkDepartment of Biochemistry, Jeonbuk National University Medical School, Jeonju, Jeollabuk‑do 54907, Republic of Korea.
Ju-Seog LeeDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Soo Mi KimDepartment of Physiology, Jeonbuk National University Medical School, Jeonju, Jeollabuk‑do 54907, Republic of Korea.
Jeonbuk National University · KRThe University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is one of the deadliest malignant tumors worldwide and its prevalence is increasing in South Korea. The efficacy of combined treatment with natural product‑derived and chemotherapy agents including curcumin combined with 5‑fluorouracil, resveratrol combined with cisplatin and epigallocatechin‑3‑gallate (EGCG) combined with cisplatin in preventing cancer progression and killing cancer cells has emerged. The Akt and Hippo signaling pathways serve a key role in colorectal tumor growth; however, the exact role of the crosstalk between Akt and Hippo signaling pathways in CRC remains poorly elucidated. The combined effect of UA and DOX on the cell proliferation, apoptosis, migration and cell cycle of CRC cells were investigated by performing Cell proliferation assay, a soft agar colony formation assay, flow cytometry, wound healing assay and western blotting assay. Subsequently, the expression of AKT and Hippo signaling pathway‑associated proteins were also assessed by western blot assay. Moreover, a xenograft nude mouse model was constructed to verify the effects of UA and DOX on the tumorigenesis of HCT116 cell

Indexed as

Colorectal NeoplasmsPhosphatidylinositol 3-KinasesAnimalsApoptosisCarcinogenesisCell ProliferationCisplatinDoxorubicinGlycogen Synthase Kinase 3 betaHippo Signaling PathwayHumansMammalsMiceProto-Oncogene Proteins c-aktSignal TransductionUrsolic AcidCisplatinDoxorubicinGlycogen Synthase Kinase 3 betaPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktUrsolic AcidAktcolorectal cancer cellsdoxorubicinHippo signaling pathwayursolic acidyes‑associated protein 1

Identifiers

PMID36382656
PMCPMC9685224
OpenAlexW4309209033

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.